Semaglutide 5mg

Semaglutide is a synthetic GLP-1 (glucagon-like peptide-1) receptor agonist that has become a cornerstone compound in metabolic and obesity research. With 94% structural homology to native human GLP-1 and strategic amino acid substitutions, this peptide exhibits significantly enhanced resistance to DPP-4 enzymatic degradation, making it exceptionally valuable for extended-duration laboratory studies. Research applications for Semaglutide span multiple domains including glucose homeostasis mechanisms, appetite regulation pathways, and cardiovascular function studies. Published literature demonstrates its utility in investigating incretin signaling, pancreatic beta-cell function, and central nervous system appetite centers. Research Applications GLP-1 receptor studies Glucose homeostasis research Appetite regulation mechanisms Metabolic pathway investigations Pancreatic function studies For laboratory research use only.

FDA-approved for: - Type 2 diabetes (Ozempic) - Chronic weight management (Wegovy) - Cardiovascular risk reduction - NASH research - Alzheimer's prevention studies - Addiction research - PCOS management

GLP-1 receptor agonist: 1. Enhances insulin secretion (glucose-dependent) 2. Suppresses glucagon secretion 3. Slows gastric emptying 4. Reduces appetite via hypothalamus 5. Improves beta cell function 6. Cardiovascular protection 7. Neuroprotective effects

Significant weight loss (15-20%) Improved glycemic control Cardiovascular protection Reduced inflammation Potential neuroprotection Improved lipid profiles Blood pressure reduction NASH improvement

FDA-approved dosing: - Starting: 0.25mg weekly for 4 weeks - Titration: 0.5mg weekly for 4 weeks - Maintenance: 1mg-2.4mg weekly - Weight loss: Up to 2.4mg weekly - Inject same day each week

Common side effects: - Nausea (most common) - Vomiting - Diarrhea - Constipation - Abdominal pain - Decreased appetite - Fatigue - Rare: pancreatitis, gallbladder issues